Stifel lowered the firm’s price target on LivaNova (LIVN) to $60 from $72 and keeps a Buy rating on the shares. Three potential “story shifting catalysts are ahead in 2025,” including the SNIA litigation final supreme court ruling, OSPREY obstructive-sleep-apnea data and the RECOVER depression trial final CMS data submission, the analyst tells investors after the company reported Q4 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova price target lowered to $60 from $72 at Baird
- LivaNova downgraded to Peer Perform from Outperform at Wolfe Research
- LivaNova PLC Reports Strong 2024 Financial Performance
- LivaNova’s Growth Potential Amid Challenges: Buy Rating Reaffirmed by Analyst
- Morning Movers: Home Depot, Keurig Dr Pepper higher after Q4 results